PepGen (PEPG) Prices $125M Offering at $5.00 per Share
PepGen priced 25M shares at $5.00 each, raising $125M before costs. Underwriters have a 30-day option for 3.75M more shares. The company did not provide prior-period comparisons.
How this was made

The 30-second read
Why it matters
The infusion of $125M strengthens the balance sheet but adds dilution, likely pressuring the stock in the short term.
Market read
First report of a sizable equity raise for a micro‑cap biotech, providing new trading information.
What to watch
Potential strategic partnership or pipeline milestones that may follow the capital infusion.
Background
PepGen announced a primary public offering of 25M shares at $5.00 each, with a 30‑day over‑allotment option for 3.75M additional shares.
Ticker impact
PepGen priced a $125M offering at $5.00 per share, raising $125M before costs.
likely pressure as the market prices in dilution from the $125M raise
New financing of this size is material for a micro‑cap biotech and typically triggers short‑term sell pressure.
Market effects
Biotech financing activity may signal investor appetite for clinical‑stage companies.
US biotech sector could see modest ripple as peers assess dilution risk.
Limited to biotech investors; no broad market effect.
Counterpoint
The raise could fund pivotal trials that unlock value, offsetting dilution concerns.
Key entities
- companyPepGen Inc.
Clinical‑stage biotechnology company raising capital.

